Develops nasal sprays for social anxiety disorder.
Jun 2026Revenue $2.50M/yrExpenses $72.2M/yr
No trendCash runway ≈ 6 months from Jun 2026
Figures by year
When will Vistagen Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $2.50M and expenses $72.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Mar 2026 | $1.27M | $73.4M | −$72.1M |
| Mar 2025 | $486K | $56.5M | −$56.0M |
| Mar 2024 | $1.06M | $34.1M | −$33.0M |
| Mar 2023 | −$227K | $59.0M | −$59.3M |
| Mar 2022 | $1.11M | $48.9M | −$47.8M |
| Mar 2021 | $1.09M | $19.0M | −$17.9M |
| Mar 2020 | $0.00 | $20.8M | −$20.8M |
| Mar 2018 | $0.00 | $14.2M | −$14.2M |
| Mar 2017 | $1.25M | $11.5M | −$10.2M |
| Mar 2016 | $0.00 | $17.9M | −$17.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.